• Incyte Corp., of Wilmington, Del., reported the first revenue from JAK inhibitor Jakafi (ruxolitinib), approved in November 2011 for intermediate or high-risk myelofibrosis, with fourth-quarter net product revenue of $2 million, besting consensus estimates by about $1 million.